Funded Project Details - FY2021
|Title:|| Preclinical investigation of PI3K inhibition and immune checkpoint blockade combination therapy for treatment of Merkel cell carcinoma using humanized mouse models|
||Long Beach, CA
|Congressional District Code:
||Biomedical Laboratory R&D
|| April 2020 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Merkel cell carcinoma (MCC) is an aggressive skin cancer that has quadrupled in incidence with a dismal five- year survival rate of less than 18% in advanced diseases. MCC disproportionately and predominantly affects Caucasian males older than 65 who are well represented in our Veteran population, especially for those who are deployed to high UV index tropical and subtropical zones and are not well protected due to other survival priorities. Hence, MCC has a growing impact on the VA healthcare s...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.